Keyphrases
Heart Failure
80%
Tumor Necrosis Factor-α
48%
Acute Decompensated Heart Failure
26%
Patients with Heart Failure
23%
Heart Failure with Preserved Ejection Fraction (HFpEF)
21%
Heart Failure Patients
16%
Left Ventricular Remodeling
15%
Left Ventricular Ejection Fraction
15%
Left Ventricular Function
14%
Myocytes
12%
Overexpression
11%
Warfarin
11%
Failing Heart
11%
Aspirin
10%
TNF Receptor 1 (TNFR1)
10%
Myocardium
10%
Congestive Heart Failure
9%
Inflammation
9%
Ventricular Assist Device
9%
Clinical Trials
9%
Cardiac Remodeling
9%
Inflammatory Cytokines
8%
Left Ventricular Dysfunction
8%
Inflammatory Mediators
7%
Hazard Ratio
7%
Disease Progression
7%
Chronic Heart Failure
7%
Myocardial Infarction
7%
Cardiocyte
7%
Dilated Cardiomyopathy
7%
Human Heart
6%
Clinical Outcomes
6%
Confidence Interval
6%
Gene Expression
6%
Innate Immune Response
6%
Acute Myocardial Infarction
6%
Murine Model
6%
Cardiac Ejection Fraction
6%
Sinus Rhythm
6%
Mammalian Heart
6%
Heart Failure Treatment
6%
Cardiac Function
5%
Randomized Clinical Trial
5%
Biologically Active Substances
5%
Ejection Fraction
5%
Placebo
5%
Left Ventricular Assist Device
5%
Cardiac Hypertrophy
5%
Reduced Ejection Fraction
5%
High Risk
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Tumor Necrosis Factor
34%
Cytokine
17%
Heart Ventricle Remodeling
16%
Warfarin
9%
Acetylsalicylic Acid
9%
Heart Infarction
9%
Inflammation
8%
Heart Left Ventricle Failure
8%
Clinical Trial
7%
Acute Heart Infarction
7%
Heart Failure with Reduced Ejection Fraction
6%
Placebo
6%
Acute Heart Failure
6%
Disease Exacerbation
6%
Tumor Necrosis Factor Receptor
6%
Randomized Clinical Trial
5%
Heart Muscle Ischemia
5%
Heart Failure with Preserved Ejection Fraction
5%
Heart Ventricle Hypertrophy
5%
Congestive Cardiomyopathy
5%
Infarction
5%
Valsartan/Sacubitril
5%
Medicine and Dentistry
Congestive Heart Failure
88%
Tumor Necrosis Factor
28%
Heart Ventricle Remodeling
12%
Cytokine
11%
Ejection Fraction
10%
Heart Left Ventricle Ejection Fraction
9%
Assisted Circulation
9%
Clinical Trial
8%
Cardiac Muscle Cell
8%
Cardiovascular System
8%
Ventricular Assist Device
8%
Heart Failure with Preserved Ejection Fraction
7%
Myocardium
6%
Hemodynamic
6%
Left Ventricular Assist Device
6%
Heart Left Ventricle Failure
6%
Dilated Cardiomyopathy
5%
Heart Failure with Reduced Ejection Fraction
5%
Combination Therapy
5%
Gene Expression
5%
Systolic Heart Failure
5%
Inflammatory Mediator
5%
